BioNexus Gene Lab Corp. (BGLC) Stock Price & Analysis
BioNexus Gene Lab Corp. (BGLC) — price $1.19 (0.00%), as of the Oct 23, 2026 trading session; market cap $2.88M.
Educational signal · not a buy or sell recommendation · How to read this
BioNexus Gene Lab Corp. · BGLC
BioNexus Gene Lab Corp. (BGLC) operates through two primary subsidiaries: Chemrex Corporation Sdn. Bhd., which distributes chemical raw materials across Southeast Asia, and BioNexus Gene Lab Sdn. Bhd., focused on developing non-invasive liquid biopsy tests. The company serves diverse industries, from automotive and aerospace to healthcare, specializing in early biomarker detection and industrial chemical supply.
Price as of Oct 23, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $1.19 |
| Change on the day | 0.00% |
| 52-week range | $1.07 – $5.67 |
| Market capitalisation | $2.88M |
| Shares traded on the day | 2.2K |
Price & events
Other perspectives
Council score for BioNexus Gene Lab (BGLC): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
0 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read date unavailable · not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 27, 2026, except a card that shows its own read date.
Watch the BGLC film — every key number, told as a short cinematic story
~2 min · open the film
What is BioNexus Gene Lab (BGLC), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. BioNexus Gene Lab Corp. (BGLC) is the company analyzed here. It employs 19 people and is led by Su-Leng Tan. In Q2 FY2026 it reported revenue of $76,156 and net income of -$286,451. The market values it at $2.88M.
What do the latest results show for BioNexus Gene Lab (BGLC)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $76,156.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $76,156 | -$286,451 | -$0.12 (diluted) |
| Q1 FY2026 | $22,842 | -$543,575 | -$0.22 (diluted) |
| Q4 FY2025 | $483,760 | -$1M | -$0.53 (diluted) |
| Q3 FY2025 | $3M | -$708,991 | -$0.39 (diluted) |
What are the financial strengths and risks for BioNexus Gene Lab (BGLC)?
Short answer
The distress and quality screens read Altman Z 0.61 · Piotroski F 3. Trailing ratios: ROE -37.4% · ROA -13.7% · current ratio 6.52 · earnings yield -58.1% · free-cash-flow yield -28.5%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.61 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-37.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 13, 2026
- Transactions
- 5
- Identified insiders
- 5
- Purchases
- 0
- Sales
- 0
- Other transactions
- 5
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Common Questions About BGLC
These answers are editorial: 1 of these 8 answers is drawn from the BGLC research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is BGLC a good stock to buy?
Stock Expert AI does not rate BGLC buy, sell or hold. BioNexus Gene Lab Corp. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BGLC stock price today?
The last price recorded on this page for BioNexus Gene Lab Corp. (BGLC) is $1.19, as of the Oct 23, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does BioNexus Gene Lab Corp. do?
BioNexus Gene Lab Corp. (BGLC) operates a diversified business model through two distinct subsidiaries. Its Chemrex Corporation Sdn. Bhd. arm specializes in the wholesale distribution of chemical raw materials across Malaysia, Indonesia, Vietnam, and other Southeast Asian countries, supplying crucial inputs for manufacturing in sectors like automotive, aerospace, and construction. Concurrently, its BioNexus Gene Lab Sdn. Bhd.
What are the key factors to evaluate for BGLC?
Evaluate BGLC on fundamentals, analyst consensus, and risk factors. Bhd. can significantly increase the adoption of its liquid biopsy and genetic testing services. Not financial advice.
How frequently does BGLC data refresh on this page?
BGLC's price is the last quote we recorded, from the Oct 23, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BGLC's recent stock price performance?
BioNexus Gene Lab Corp. (BGLC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified dual business model across chemical distribution and molecular diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BGLC overvalued or undervalued right now?
BioNexus Gene Lab Corp. (BGLC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BGLC before investing?
Before investing in BioNexus Gene Lab Corp. (BGLC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (14 figures)
The 14 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $1.19 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T08:34:48.345Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $2.88M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-23. FMP quote timestamp: 2026-10-23T20:00:00.000Z. Captured from FMP at 2026-10-26T08:34:47.300Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 2.2K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $76,156 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | -$286,451 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 5 transactions · 0 purchases, 0 sales, 5 other transactions · 5 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Aug 13, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $1.07 – $5.67 | UNRECORDED | Stored company-profile observation — Captured 2026-10-23 | |
id.employees | Employees | 19 | UNRECORDED | Stored company-profile observation — Captured 2026-10-23 | |
id.ceo | Chief executive | Su-Leng Tan | UNRECORDED | Stored company-profile observation — Captured 2026-10-23 | |
fin.scores | Distress and quality screens | Altman Z 0.61 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-25 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -37.4% · ROA -13.7% · current ratio 6.52 · earnings yield -58.1% · free-cash-flow yield -28.5% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.